Department of Medicine III, University Hospital of Munich, Marchioninistr. 15, 81377 Munich, Germany.
Department of Haematology and Oncology, University Hospital of Tuebingen, Otfried-Müller-Str. 3, 72076 Tuebingen, Germany.
Clin Immunol. 2022 Sep;242:109083. doi: 10.1016/j.clim.2022.109083. Epub 2022 Jul 28.
(Leukaemia derived) dendritic cells (DC, DC) are potent stimulators of anti-leukaemic activity in acute myeloid leukaemia (AML) and can be generated with immunomodulatory kits containing granulocyte-macrophage-colony-stimulating-factor (GM-CSF), prostaglandin-E (PGE), prostaglandin-E (PGE) and/or picibanil (OK-321). Potential adverse effects initiated through kits, especially the proliferation of blasts, must be ruled out to ensure treatment safety. We quantified proliferating blasts with the proliferation markers CD71 and Ki-67 and the novel proliferation marker IPO-38 before and after kit treatment ex vivo. IPO-38 hereby appeared to be the most sensitive marker; a combination with CD71 may add value when assessing proliferation kinetics. Kit treatment did not or only slightly (<5%) induce blast proliferation in most cases. An induction of blast proliferation was only found in single cases and could be compensated by DC-induced anti-leukaemic activity in most times. Overall, we appraise kit treatment to be safe in vivo.
(白血病衍生的)树突状细胞 (DC, DC) 是急性髓细胞性白血病 (AML) 中抗白血病活性的有效刺激物，并且可以通过含有粒细胞巨噬细胞集落刺激因子 (GM-CSF)、前列腺素 E (PGE)、前列腺素 E (PGE) 和/或比卡尼利 (OK-321) 的免疫调节试剂盒来生成。试剂盒引发的潜在不良反应，特别是白血病细胞的增殖，必须排除在外，以确保治疗安全。我们使用增殖标志物 CD71 和 Ki-67 以及新型增殖标志物 IPO-38 对试剂盒处理前后的 ex vivo 白血病细胞增殖进行了定量分析。IPO-38 似乎是最敏感的标志物；当评估增殖动力学时，与 CD71 结合可能会增加其价值。在大多数情况下，试剂盒处理不会或仅轻微 (<5%) 诱导白血病细胞增殖。仅在单个病例中发现了白血病细胞增殖的诱导，并且在大多数情况下可以通过 DC 诱导的抗白血病活性来补偿。总体而言，我们评估试剂盒处理在体内是安全的。
